DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316 Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024. 0

https://www.zacks.com/stock/news/2201005/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2201005 Dec 21, 2023 - With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024. 0

https://www.zacks.com/stock/news/2202432/is-spdr-msci-usa-strategicfactors-etf-qus-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-2202432 Dec 27, 2023 - Smart Beta ETF report for QUS 0

https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113 Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6. 0

https://www.zacks.com/stock/news/2221393/markets-take-a-powder-pltr-nxpi-beat-in-q4?cid=CS-ZC-FT-ahead_of_wall_street-2221393 Feb 05, 2024 - Market indices were reluctant to drag a stock market higher amid all-time high ranges on the Dow and S&P 500. 0

https://www.zacks.com/stock/news/2221920/earnings-data-deluge?cid=CS-ZC-FT-economic_highlights-2221920 Feb 06, 2024 - Earnings Data Deluge. 0

https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190 Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements. 0

https://www.zacks.com/stock/news/2225655/incyte-s-incy-q4-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2225655 Feb 13, 2024 - Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura. 0

https://www.zacks.com/commentary/2232353/top-analyst-reports-for-eli-lilly-procter-gamble-morgan-stanley?cid=CS-ZC-FT-research_daily-2232353 Feb 27, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS). 0

https://www.zacks.com/stock/news/2238098/s-p-500-soars-to-new-highs-5-best-stocks-ytd?cid=CS-ZC-FT-etf_news_and_commentary-2238098 Mar 08, 2024 - The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year. 0